Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF

The angiotensin receptor/neprilysin inhibitor Sacubitril/Valsartan (Sac/Val) has been shown to be beneficial in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, the impact of Sac/Val in patients presenting with heart failure with preserved ejection fraction (HFp...

Descripción completa

Detalles Bibliográficos
Autores principales: Schauer, Antje, Adams, Volker, Augstein, Antje, Jannasch, Anett, Draskowski, Runa, Kirchhoff, Virginia, Goto, Keita, Mittag, Jeniffer, Galli, Roberta, Männel, Anita, Barthel, Peggy, Linke, Axel, Winzer, Ephraim B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036273/
https://www.ncbi.nlm.nih.gov/pubmed/33808232
http://dx.doi.org/10.3390/ijms22073570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036273/
https://www.ncbi.nlm.nih.gov/pubmed/33808232
http://dx.doi.org/10.3390/ijms22073570

Ejemplares similares